US 12,324,807 B2
Combination therapy for PI3K-associated disease or disorder
Lewis C. Cantley, Cambridge, MA (US); Benjamin Hopkins, Larchmont, NY (US); Marcus Goncalves, Garden City, NY (US); and Siddhartha Mukherjee, New York, NY (US)
Assigned to Cornell University, Ithaca, NY (US); and The Trustees of Columbia University, New York, NY (US)
Appl. No. 15/733,852
Filed by Cornell University, Ithaca, NY (US); and The Trustees of Columbia University, New York, NY (US)
PCT Filed May 31, 2019, PCT No. PCT/US2019/034949
§ 371(c)(1), (2) Date Nov. 30, 2020,
PCT Pub. No. WO2019/232403, PCT Pub. Date Dec. 5, 2019.
Claims priority of provisional application 62/679,329, filed on Jun. 1, 2018.
Prior Publication US 2021/0236501 A1, Aug. 5, 2021
Int. Cl. A61K 31/5377 (2006.01); A61K 31/155 (2006.01); A61K 31/4375 (2006.01); A61K 31/4439 (2006.01); A61K 31/4745 (2006.01); A61K 31/4985 (2006.01); A61K 31/553 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/5377 (2013.01) [A61K 31/155 (2013.01); A61K 31/4375 (2013.01); A61K 31/4439 (2013.01); A61K 31/4745 (2013.01); A61K 31/4985 (2013.01); A61K 31/553 (2013.01); A61P 35/00 (2018.01)] 40 Claims
 
1. A method of improving the efficacy of a PI3K inhibitor in a treatment of a patient with a cancer that is pancreatic, breast, endometrial, bladder, leukemia, lung, or liver cancer the method comprising administering to the patient a PI3K inhibitor selected from copanlisib, buparlisib, alpelisib, taselisib, pictilisib or serabelisib in combination with a ketogenic diet that reduces serum insulin levels thereby improving the efficacy of the PI3K inhibitor wherein the ketogenic diet comprises at least 80% of fat and protein by weight.